DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Lasseigne, Brittany N ^a,b   Burwell, Todd C ^a   Patil, Mohini A ^c   Absher, Devin M ^a   Brooks, James D ^c   Myers, Richard M ^a  

^a HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY   (United States)

^b University of Alabama in Huntsville   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Cancer; Diagnostic biomarker; DNA methylation; Kidney; Renal cell carcinoma

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GAMMA GLUTAMYLTRANSFERASE; TUMOR MARKER; VON HIPPEL LINDAU PROTEIN;

AREA UNDER THE CURVE; ARTICLE; CPG ISLAND; DNA METHYLATION; ENERGY METABOLISM; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSTICS; PROMOTER REGION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; WNT SIGNALING PATHWAY; ADULT; AGED; CARCINOMA, RENAL CELL; EVALUATION STUDY; FEMALE; GENETICS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; DNA METHYLATION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 84924026193     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-014-0235-x     Document Type: Article

References (70)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Chow W-HWH, Devesa SS, Warren JL, Fraumeni JF: Rising Incidence of Renal Cell Cancer in the United States. JAMA 1999, 281:1628-1631.
3. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ CK (Eds): SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 2009.
4. Bhatt JR, Finelli A: Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol 2014, 11:517-525.
5. Lightfoot N, Conlon M, Kreiger N, Bissett R, Desai M, Warde P, Prichard HM: Impact of noninvasive imaging on increased incidental detection of renal cell carcinoma. Eur Urol 2000, 37:521-527.
6. Silverman SG, Israel GM, Herts BR, Richie JP: Management of the incidental renal mass. Radiology 2008, 249:16-31.
7. Jeon HG, Lee SR, Kim KH, Oh YT, Cho NH, Rha KH, Yang SC, Han WK: Benign lesions after partial nephrectomy for presumed renal cell carcinoma in masses 4 cm or less: prevalence and predictors in Korean patients. Urology 2010, 76:574-579.
8. Bradley AJ, Lim YY, Singh FM: Imaging features, follow-up, and management of incidentally detected renal lesions. Clin Radiol 2011, 66:1129-1139.
9. Lipsky MJ, Shapiro EY, Hruby GW, McKiernan JM: Diagnostic radiation exposure during surveillance in patients with pT1a renal cell carcinoma. Urology 2013, 81:1190-1195.
10. Sodickson A, Baeyens PF, Andriole KP, Prevedello LM, Nawfel RD, Hanson R, Khorasani R: Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 2009, 251:175-184.
11. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK: State of the science: an update on renal cell carcinoma. Mol Cancer Res 2012, 10:859-880.
12. Bielecka ZF, Czarnecka AM, Szczylik C: Genomic analysis as the first step toward personalized treatment in renal cell carcinoma. Front Oncol 2014, 4:194.
13. Rini BI, Campbell SC, Escudier B: Renal cell carcinoma. Lancet 2009, 373:1119-1132.
14. Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991-5004.
15. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R: Update on the classification of renal epithelial tumors in adults. Int J Urol 2009, 2009:432-443.
16. Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, Greenberg RE, Cairns P: Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 2003, 63:8695-8699.
17. Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, Califano J, Sidransky D: Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 2004, 64:5511-5517.
18. Hauser S, Zahalka T, Fechner G, Müller SC, Ellinger J: Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. Anticancer Res 2013, 33:4651-4656.
19. Arai E, Chiku S, Mori T, Gotoh M, Nakagawa T, Fujimoto H, Kanai Y: Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis 2012, 33:1487-1493.
20. Arai E, Wakai-Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y: Genome-wide DNA methylation profiles in renal tumors of various histological subtypes and non-tumorous renal tissues. Pathobiology 2011, 78:1-9.
21. Arai E, Ushijima S, Tsuda H: Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome genetic clustering of clear cell renal cell carcinoma based on. Clin Cancer Res 2008, 14:5531-5539.
22. Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, Clarke N, Latif F, Maher ER: Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 2011, 30:1390-1401.
23. McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, Ragoussis J, Clarke NW, Brown MD, Kishida T, Yao M, Latif F, Maher ER: CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer 2009, 8:31.
24. Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Gordon Robertson A, Chu A, Beroukhim R, Cibulskis K, Signoretti S, Vandin Hsin-Ta Wu F, Raphael BJ, Verhaak RGW, Tamboli P, Torres-Garcia W, Akbani R, Weinstein JN, Reuter V, Hsieh JJ, Rose Brannon A, Ari Hakimi A, Jacobsen A, Ciriello G, Reva B, Ricketts CJ, Marston Linehan W, Stuart JM, Kimryn Rathmell W, Shen H, Laird PW, et al: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
25. Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002, 99:6567-6572.
26. Johnson WE, Li C, Rabinovic A: Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8:118-127.
27. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, Mckenney JK, Peehl DM, Brooks JD, Myers RM, Sherlock G: DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 2011, 21:1017-1027.
28. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95:14863-14868.
29. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z: GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 2009, 10:48.
30. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267-273.
31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
32. Day K, Waite LL, Thalacker-Mercer A, West A, Bamman MM, Brooks JD, Myers RM, Absher D: Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. Genome Biol 2013, 14:R102.
33. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
34. Wozniak MB, Le Calvez-Kelm F, Abedi-Ardekani B, Byrnes G, Durand G, Carreira C, Michelon J, Janout V, Holcatova I, Foretova L, Brisuda A, Lesueur F, McKay J, Brennan P, Scelo G: Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States. PLoS One 2013, 8:e57886.
35. Dalgin GS, Holloway DT, Liou LS, DeLisi C: Identification and characterization of renal cell carcinoma gene markers. Cancer Inform 2007, 3:65-92.
36. Zeng Z, Que T, Zhang J, Hu Y: A study exploring critical pathways in clear cell renal cell carcinoma. Exp Ther Med 2014, 7:121-130.
37. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin M-L, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, et al: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
38. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin M-L, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LFA, Richard S, Kahnoski RJ, Anema J, et al: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
39. Heisterkamp N, Groffen J, Warburton D, Sneddon TP: The human gamma-glutamyltransferase gene family. Hum Genet 2008, 123:321-332.
40. Lertratanangkoon K, Wu CJ, Savaraj N, Thomas ML: Alterations of DNA methylation by glutathione depletion. Cancer Lett 1997, 120:149-156.
41. Carl JW, Bai X-F: IL27: its roles in the induction and inhibition of inflammation. Int J Clin Exp Pathol 2008, 1:117-123.
42. Long J, Zhang X, Wen M, Kong Q, Lv Z, An Y, Wei X-Q: IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun 2013, 430:364-369.
43. Dou R, Deng Y, Huang L, Fu S, Tan S, Wang L, Lian L, Fang L, Fan X, Jin G, Liu H, Wang J: Multi-microarray identifies lower AQP9 expression in adjuvant chemotherapy nonresponders with stage III colorectal cancer. Cancer Lett 2013, 336:106-113.
44. Yu H-F, Zhao G, Ge Z-J, Wang D-R, Chen J, Zhang Y, Zha T-Z, Zhang K, Zhang M, Tan Y-F, Zhou S-J, Jiang C: High RIN1 expression is associated with poor prognosis in patients with gastric adenocarcinoma. Tumour Biol 2012, 33:1557-1563.
45. He H, Wu G, Liu H, Cheng Y, Yu Y, Wang Y, Liu Y: Low RIN1 Expression in HCC Is Associated With Tumor Invasion and Unfavorable Prognosis. Am J Clin Pathol 2013, 140:73-81.
46. Fang P, Zhao Z, Tian H, Zhang X: RIN1 exhibits oncogenic property to suppress apoptosis and its aberrant accumulation associates with poor prognosis in melanoma. Tumour Biol 2012, 33:1511-1518.
47. Shan G, Zhang Z, Chen Q, Yu X, Liu G, Kong C: Overexpression of RIN1 associates with tumor grade and progression in patients of bladder urothelial carcinoma. Tumour Biol 2012, 33:847-855.
48. Ashour N, Angulo JC, Andrés G, Alelú R, González-Corpas A, Toledo MV, Rodríguez-Barbero JM, López JI, Sánchez-Chapado M, Ropero S: A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis. Prostate 2014, 74:1171-1182.
49. Salhia B, Kiefer J, Ross JTD, Metapally R, Martinez RA, Johnson KN, DiPerna DM, Paquette KM, Jung S, Nasser S, Wallstrom G, Tembe W, Baker A, Carpten J, Resau J, Ryken T, Sibenaller Z, Petricoin EF, Liotta LA, Ramanathan RK, Berens ME, Tran NL: Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS One 2014, 9:e85448.
50. Roperch J-P, Incitti R, Forbin S, Bard F, Mansour H, Mesli F, Baumgaertner I, Brunetti F, Sobhani I: Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer 2013, 13:566.
51. Kishida Y, Natsume A, Kondo Y, Takeuchi I, An B, Okamoto Y, Shinjo K, Saito K, Ando H, Ohka F, Sekido Y, Wakabayashi T: Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis 2012, 33:436-441.
52. Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, Czerniak B, Issa J-PJ: Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev 2011, 20:1483-1491.
53. Chung J-H, Lee HJ, Kim B-H, Cho N-Y, Kang GH: DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch 2011, 459:201-211.
54. Olkhov-Mitsel E, Van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C, Recker F, Kwiatkowski M, Fleshner NE, Diamandis EP, Zlotta AR, Bapat B: Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics 2012, 7:1037-1045.
55. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, Wang J, Chen L: Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011, 303:21-28.
56. Worsham MJ, Chen KM, Meduri V, Nygren AOH, Errami A, Schouten JP, Benninger MS: Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006, 132:668-677.
57. Wang LJ, Jin HC, Wang X, Lam EKY, Zhang J, Bin, Liu X, Chan FKL, Si JM, Sung JJY: ZIC1 is downregulated through promoter hypermethylation in gastric cancer. Biochem Biophys Res Commun 2009, 379:959-963
58. Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJB, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G: ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. J Thorac Oncol 2013, 8:1317-1328.
59. Huang R-L, Gu F, Kirma NB, Ruan J, Chen C-L, Wang H-C, Liao Y-P, Chang C-C, Yu M-H, Pilrose JM, Thompson IM, Huang H-C, Huang TH-M, Lai H-C, Nephew KP: Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. Epigenetics 2013, 8:624-634.
60. Milstein M, Mooser CK, Hu H, Fejzo M, Slamon D, Goodglick L, Dry S, Colicelli J: RIN1 is a breast tumor suppressor gene. Cancer Res 2007, 67:11510-11516.
61. Zhang Y-W, Zheng Y, Wang J-Z, Lu X-X, Wang Z, Chen L-B, Guan X-X, Tong J-D: Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. Epigenetics 2014, 9:896-909.
62. Wang J, Wang L, Zhang D, Fan Y, Jia Z, Qin P, Yu J, Zheng S, Yang F: Identification of potential serum biomarkers for Wilms tumor after excluding confounding effects of common systemic inflammatory factors. Mol Biol Rep 2012, 39:5095-5104.
63. Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, Schellens JH, Beijnen JH, Voest EE: Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol 2010, 21:1472-1481.
64. Paret C, Schön Z, Szponar A, Kovacs G: Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur Urol 2010, 57:859-866.
65. Grützmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, Miehlke S, Stolz T, Model F, Roblick UJ, Bruch H-P, Koch R, Liebenberg V, Devos T, Song X, Day RH, Sledziewski AZ, Lofton-Day C: Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008, 3:e3759.
66. deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grützmann R, Pilarsky C, Habermann JK, Fleshner PR, Oubre BM, Day R, Sledziewski AZ, Lofton-Day C: Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009, 55:1337-1346.
67. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SMJ, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J: PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007, 69:532-535.
68. Deras IL, Aubin SMJ, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J: PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008, 179:1587-1592.
69. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA, Huland H, Abbou C-C, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MPMQ, Schalken JA: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008, 54:1081-1088.
70. Durand X, Moutereau S, Xylinas E, de la Taille A: Progensa™ PCA3 test for prostate cancer. Expert Rev Mol Diagn 2011, 11:137-144.